Search

Your search keyword '"Tobe, Sheldon"' showing total 117 results

Search Constraints

Start Over You searched for: Author "Tobe, Sheldon" Remove constraint Author: "Tobe, Sheldon" Database Supplemental Index Remove constraint Database: Supplemental Index
117 results on '"Tobe, Sheldon"'

Search Results

1. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes

2. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

6. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

7. Strategic, Successful, and Sustained Synergy: The Global Alliance for Chronic Diseases Hypertension Program.

8. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

9. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children

10. Hypertension Canada’s 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension

11. The Malawi NCD BRITE Consortium: Building Research Capacity, Implementation, and Translation Expertise for Noncommunicable Diseases.

12. Systematic Review of Hypertension and Diabetes Burden, Risk Factors, and Interventions for Prevention and Control in Malawi: The NCD BRITE Consortium.

14. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

15. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

16. Guideline Alignment in Related Areas

17. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

20. Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions).

21. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children

22. Thresholds and Targets for Hypertension Management in Adults With Type 2 Diabetes Should Remain at 130/80 mmHg: What's the Evidence?

24. Steady-State Pharmacokinetics of Oral Ciprofloxacin in Continuous Cycling Peritoneal Dialysis Patients: Brief Report

25. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults

26. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes

27. Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries

29. Regional and physician specialty–associated variations in the medical management of atherosclerotic renal–artery stenosis.

30. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

31. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events

32. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

33. Preventing Cardiovascular and Renal Disease in Canada's Aboriginal Populations

34. The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

35. A New Algorithm for the Diagnosis of Hypertension in Canada

37. Measurement of blood pressure in the office: recognizing the problem and proposing the solution.

39. Renal denervation for human hypertension: is there a future?

40. Is there a preferred diuretic class for patients with renal impairment and hypertension?

41. Should age determine hypertension management? Recommendations from current guidelines.

42. Angiotensin inhibition in renovascular disease: A population-based cohort study.

43. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD

44. Contemporary Use of β-Blockers: Clinical Relevance of Subclassification

45. Combining Other Antihypertensive Drugs With β-Blockers in Hypertension: A Focus on Safety and Tolerability

46. β-Blockers in Hypertension: Studies and Meta-analyses Over the Years

47. The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

48. Renal Denervation Therapy for the Treatment of Resistant Hypertension: A Position Statement by the Canadian Hypertension Education Program

49. The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

50. Hypertension Management Initiative: Qualitative Results From Implementing Clinical Practice Guidelines in Primary Care Through a Facilitated Practice Program

Catalog

Books, media, physical & digital resources